Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic

Aims. Sub-analysis of a retrospective nation-wide observational analysis of heart failure (HF) epidemiology reported to the Czech National Registry of Reimbursed Health Services between 2012 and 2018 aimed at beta-blockers (BBs) utilization. Methods and Results. The beta-blockers were generally used...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Milos Taborsky, Renata Aiglova, Marie Lazarova, Ludek Pavlu, Josef Danek, Jan Precek, Alexander Schee, Vit Gloger, Marek Vicha, Tomas Skala
Formato:	article
Lenguaje:	EN
Publicado:	Palacký University Olomouc, Faculty of Medicine and Dentistry 2021
Materias:	beta-blockers heart failure treatment Medicine R
Acceso en línea:	https://doaj.org/article/cdf5705afc8b49d791425af7f24c1883
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cdf5705afc8b49d791425af7f24c1883
record_format	dspace
spelling	oai:doaj.org-article:cdf5705afc8b49d791425af7f24c18832021-11-29T09:17:21ZBeta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic1213-81181804-7521https://doaj.org/article/cdf5705afc8b49d791425af7f24c18832021-11-01T00:00:00Zhttps://biomed.papers.upol.cz/artkey/bio-202104-0009_beta-blockers-utilization-in-heart-failure-patients-sub-analysis-of-a-nation-wide-population-based-study-in-th.phphttps://doaj.org/toc/1213-8118https://doaj.org/toc/1804-7521Aims. Sub-analysis of a retrospective nation-wide observational analysis of heart failure (HF) epidemiology reported to the Czech National Registry of Reimbursed Health Services between 2012 and 2018 aimed at beta-blockers (BBs) utilization. Methods and Results. The beta-blockers were generally used in 81.8% of all patients treated for HF in 2012 (n=52 140); 81.8% in 2013 (n=53 058); 83.1% in 2014 (n=56 221); 82.1% in 2015 (n=57 421); 83.3% in 2016 (n=59 187); 82.2% in 2017 (60 058) and in 81.4% in 2018 (n=60 966). In 2018, the majority of patients treated for HF were prescribed metoprolol (22 974; 30.7%) and bisoprolol (21 001; 28%). Carvedilol was prescribed in 7 331 patients treated for HF (9.8%), nebivolol in 5 392 HF patients. Despite its primary indication, betaxolol was used in 2 341 patients treated for HF (3.1%). All other beta-blockers were used in less than 1% of HF patients. In some of the mostly used BBs, their prescription in patients treated for HF changed in the last years (metoprolol 32.4% in 2012, 30.7% in 2018; bisoprolol 20.3% in 2012, 28% in 2018; carvedilol 18.3% in 2012, 9.8% in 2018; nebivolol 2.5% in 2012, 7.2% in 2018; betaxolol 4.2% in 2012, 3.1% in 2018). Conclusion. In an analysis of beta-blockers utilization in all patients treated for heart failure in the given year in the whole country, we have found only slightly lower amount of drug prescription in comparison with specific heart failure registries. This indicates a good translation of current standard of care into common clinical practice. Metoprolol remained the mostly prescribed drug. The prescription of bisoprolol and nebivolol has increased at the expense of carvedilol.Milos TaborskyRenata AiglovaMarie LazarovaLudek PavluJosef DanekJan PrecekAlexander ScheeVit GlogerMarek VichaTomas SkalaPalacký University Olomouc, Faculty of Medicine and Dentistryarticlebeta-blockersheart failuretreatmentMedicineRENBiomedical Papers, Vol 165, Iss 4, Pp 402-407 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	beta-blockers heart failure treatment Medicine R
spellingShingle	beta-blockers heart failure treatment Medicine R Milos Taborsky Renata Aiglova Marie Lazarova Ludek Pavlu Josef Danek Jan Precek Alexander Schee Vit Gloger Marek Vicha Tomas Skala Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic
description	Aims. Sub-analysis of a retrospective nation-wide observational analysis of heart failure (HF) epidemiology reported to the Czech National Registry of Reimbursed Health Services between 2012 and 2018 aimed at beta-blockers (BBs) utilization. Methods and Results. The beta-blockers were generally used in 81.8% of all patients treated for HF in 2012 (n=52 140); 81.8% in 2013 (n=53 058); 83.1% in 2014 (n=56 221); 82.1% in 2015 (n=57 421); 83.3% in 2016 (n=59 187); 82.2% in 2017 (60 058) and in 81.4% in 2018 (n=60 966). In 2018, the majority of patients treated for HF were prescribed metoprolol (22 974; 30.7%) and bisoprolol (21 001; 28%). Carvedilol was prescribed in 7 331 patients treated for HF (9.8%), nebivolol in 5 392 HF patients. Despite its primary indication, betaxolol was used in 2 341 patients treated for HF (3.1%). All other beta-blockers were used in less than 1% of HF patients. In some of the mostly used BBs, their prescription in patients treated for HF changed in the last years (metoprolol 32.4% in 2012, 30.7% in 2018; bisoprolol 20.3% in 2012, 28% in 2018; carvedilol 18.3% in 2012, 9.8% in 2018; nebivolol 2.5% in 2012, 7.2% in 2018; betaxolol 4.2% in 2012, 3.1% in 2018). Conclusion. In an analysis of beta-blockers utilization in all patients treated for heart failure in the given year in the whole country, we have found only slightly lower amount of drug prescription in comparison with specific heart failure registries. This indicates a good translation of current standard of care into common clinical practice. Metoprolol remained the mostly prescribed drug. The prescription of bisoprolol and nebivolol has increased at the expense of carvedilol.
format	article
author	Milos Taborsky Renata Aiglova Marie Lazarova Ludek Pavlu Josef Danek Jan Precek Alexander Schee Vit Gloger Marek Vicha Tomas Skala
author_facet	Milos Taborsky Renata Aiglova Marie Lazarova Ludek Pavlu Josef Danek Jan Precek Alexander Schee Vit Gloger Marek Vicha Tomas Skala
author_sort	Milos Taborsky
title	Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic
title_short	Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic
title_full	Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic
title_fullStr	Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic
title_full_unstemmed	Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic
title_sort	beta-blockers utilization in heart failure patients: sub-analysis of a nation-wide population-based study in the czech republic
publisher	Palacký University Olomouc, Faculty of Medicine and Dentistry
publishDate	2021
url	https://doaj.org/article/cdf5705afc8b49d791425af7f24c1883
work_keys_str_mv	AT milostaborsky betablockersutilizationinheartfailurepatientssubanalysisofanationwidepopulationbasedstudyintheczechrepublic AT renataaiglova betablockersutilizationinheartfailurepatientssubanalysisofanationwidepopulationbasedstudyintheczechrepublic AT marielazarova betablockersutilizationinheartfailurepatientssubanalysisofanationwidepopulationbasedstudyintheczechrepublic AT ludekpavlu betablockersutilizationinheartfailurepatientssubanalysisofanationwidepopulationbasedstudyintheczechrepublic AT josefdanek betablockersutilizationinheartfailurepatientssubanalysisofanationwidepopulationbasedstudyintheczechrepublic AT janprecek betablockersutilizationinheartfailurepatientssubanalysisofanationwidepopulationbasedstudyintheczechrepublic AT alexanderschee betablockersutilizationinheartfailurepatientssubanalysisofanationwidepopulationbasedstudyintheczechrepublic AT vitgloger betablockersutilizationinheartfailurepatientssubanalysisofanationwidepopulationbasedstudyintheczechrepublic AT marekvicha betablockersutilizationinheartfailurepatientssubanalysisofanationwidepopulationbasedstudyintheczechrepublic AT tomasskala betablockersutilizationinheartfailurepatientssubanalysisofanationwidepopulationbasedstudyintheczechrepublic
_version_	1718407429499125760

Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic

Ejemplares similares